News
25 October, 2022 - 19:50 (CEST)
Alerts
M
New Invitation for Expression of Interest (EOI) to manufacturers and suppliers of medicinal products for treatment of hepatitis B and C.
The following products were added:
- Antivirals as fixed-dose combinations (FDC) for adults and adolescents
- Glecaprevir/Pibrentasvir, tablet 100mg/40mg
- Glecaprevir/Pibrentasvir, tablet 100mg/40mg
- Antivirals as single-ingredient formulations for use in children: Paediatric formulations
- Daclatasvir, tablet 30mg (preferably dispersible)
- Sofosbuvir, tablet 100mg (preferably dispersible)
The following products were deleted:
- Dasabuvir tablet 250mg
- Ombitasvir/Paritaprevir/Ritonavir tablet 25mg/150mg/100mg